Status:
COMPLETED
Insulin Detemir Compared to Insulin Glargine: Appetite and Calories Consumed in Type 1 Diabetes
Lead Sponsor:
University of New Mexico
Conditions:
Diabetes Mellitus
Eligibility:
All Genders
18-60 years
Phase:
NA
Brief Summary
Patients with diabetes treated with insulin often gain weight, which may deter patients from adhering to insulin treatment. Detemir is one type of long acting insulin approved by the Food and Drug Adm...
Detailed Description
Insulin detemir is a neutral, soluble long acting insulin analog with weight neutral properties. In limited studies, it has been shown to result in less weight gain in type 1 and type 2 diabetics comp...
Eligibility Criteria
Inclusion
- Type 1 diabetes
- Treated with long-acting and meal time insulin therapy for at least 2 years
- Ages 18 to 60 years of age
- Glycosylated hemoglobin value between 7 - 9 mg/dL
- C-peptide value less than 1.0 pmol/ml 90 minutes after oral Boost Plus administration.
Exclusion
- Advanced complications of diabetes (nephropathy, retinopathy, significant neuropathy, coronary artery disease)
- Severe medical illness or medical conditions including congestive heart failure, angina, liver failure or renal failure
- Pregnancy
- Alcohol or drug abuse or dependence within three months of study entry
- Less than 50 % agreement on 50-item Food Questionnaire with the Food Array "buffet style" study meal.
- Women of child-bearing age not adhering to the following contraceptive methods: oral contraceptives, barrier methods including condoms or diaphragm, or abstinence.
Key Trial Info
Start Date :
April 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2011
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT00659165
Start Date
April 1 2008
End Date
January 1 2011
Last Update
March 22 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of New Mexico Health Sciences Center
Albuquerque, New Mexico, United States, 87131